Commercialization Success OBEST...

With the global economy still in recovery two years after the economic downturn, Ontario’s bioscience industry and a universe if pan- Ontario stakeholders seized the opportunity to contribute to Ontario’s economic growth and developed a comprehensive, implementable plan for a vibrant biosciences industry. Developed by OBIO, the plan is named, OBEST (Ontario Biosciences Economic Strategy Team) and articles...

Ontario’s Bioscience Industry – Transl...

The Ontario Bioscience Industry Organization (OBIO) works to advance the development and growth of a sustainable, commercially – driven, life sciences industry in Ontario. OBIO is a private sector, membership-based organization representing Ontario’s human-health bioscience industry. Key among Ontario’s bioscience strengths are a pipeline of high value, early stage intellectual property and start-up...

Leveraging the $7 Million Fund – Designated ...

During the fall of 2009, with Ontario’s bioscience industry fighting for survival due to an inability to raise capital in the midst of a world-wide economic crisis, OBIO mobilized industry CEOs to take action. With a sense of urgency derived from the need for a plan to ensure the survival of the industry, OBIO organized its first province-wide consultation process ultimately generating a set of recommendations for industry...

The Best Laid Plans – How OBIO™ is loo...

Innovation and Bioscience go hand and hand. It is a symbiotic relationship – both depend on one another. Yet, for Ontario, a province teeming with groundbreaking initiatives in the bioscience field, there is something missing. A broken link between this would-be flourishing industry and reality. True, the recession of 2008 to 2009 hit the industry hard, but the seeds of insufficiency were planted far earlier. For most...

Q3 2010 Canadian Healthcare Review...

Financings A weak financing climate for Canadian public healthcare companies continued in the third quarter. Gross proceeds of equity and convertible debt financings completed in the third quarter amounted to $65.5 million (Appendix 1), bringing the total for the first nine months of 2010 to $374.2 million.  In order to get a true assessment of the financing situation for public development stage companies, financings for...

Q2 2010 Canadian Healthcare Review...

Financing, A weak financing climate for Canadian public healthcare companies continued in the second quarter. Gross proceeds of completed equity and convertible debt financings amounted to $72.7 million (Appendix 1), bringing the total for the first half of 2010 to $308.7 million. Two issuers accounted for more than half of the activity in the second quarter: Aeterna Zentaris completed two equity financings totaling US$27.1...

Q1 2010 Canadian Healthcare Review...

Financing Public Canadian healthcare companies completed equity and convertible debt financings during this quarter for total gross proceeds of $236.0 million (Appendix 1). The largest financing in the sector was the only financing in the Services group, $86.3 million by Extendicare. The largest financing in the Therapeutics group was $34.5 million from a rights offering by Wex Pharmaceuticals, with 97.6% of the shares being...

CEOs Speak Out About Issues Affecting Their Abilit...

By Gail Garland In the summer of 2009, the CEOs of Ontario’s SME bioscience companies came together at the open invitation of Ontario Bioscience Industry Organization (OBIO) for a meeting hosted in Gowlings Toronto boardroom. On the agenda was a discussion of the future of Ontario’s bioscience industry and its unprecedented lack of access to capital, a worsening situation threatening the sustainability of the...

BURRILL CANADIAN BIOTECH NEWS...

“The Ontario Government is listening to our industry and recognizing the economic potential of a vibrant and growing bioscience industry that can produce many of the medical therapies and technologies we now import and can create jobs”, said Dr. David Young, chair of the board of directors of OBIO, and managing partner, Actium Equity Partners. View PDF: ...

Innovation and Commercialization Seminar Series at...

University of Toronto, Faculty of Medicine is hosting 3 seminars on Innovation and Commercialization: Commercialization:  March 18 (view pdf) Intellectual Property:  April 15 Business Planning:  May...